Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 8/2018

01-08-2018 | Original Contributions

Intragastric Balloons for Overweight Populations—1 Year Post Removal

Authors: Dean Keren, Tova Rainis

Published in: Obesity Surgery | Issue 8/2018

Login to get access

Abstract

Background

Endoscopic balloons have been used for years to treat obese seeking weight loss. This study evaluated the safety and effectiveness of our lifestyle modification program.

Methods

Retrospective analysis of prospectively collected data from patients who underwent End-ball® (Endalis) intragastric balloon insertion with a multidisciplinary follow-up program. Demographic data, weight loss complications, and satisfaction rates were assessed.

Results

In total, 114 overweight/obese individuals from July 2012 to December 2015 were included. Mean age 36.5 years (72% females). Initial body mass index (BMI) was 33.5 kg/m2. Twelve early removals (10.52%) due to intolerance (n = 7), dissatisfaction (n = 4), and esophagitis (n = 1); 102 patients completed the program. BMI reduction ranged 5.5–6.4 at balloon removal and 4.1 1-year post removal. Average excess BMI loss (EBMIL) was 46–48% at balloon removal and 39.1% after 1 year; 75% of participants maintained > 60% of their weight loss 1 year after removal. EBMIL was 17 and 48% when initial BMI > 35 and ≤ 35 kg/m2, respectively. At removal, 80% of patients were satisfied with the process.

Conclusion

The End-ball® program resulted in significant weight loss that continued for 1 year after balloon removal, with minimal complications. When treating overweight/obese populations, the main principles of the balloon insertion process should be no complications, high safety, and significant effectiveness. The process was most beneficial in the overweight and class I obese populations since average BMI was 33 and the class II obese had less weight loss and can possibly prevent future bariatric surgery.
Literature
1.
James PT, Rigby N, Leach R. International Obesity Task Force—the obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil. 2004;11 (1):3–.
2.
Overweight, obesity, health risk: National Task Force on the prevention and treatment of obesity. Arch Intern Med. 2000;160:898–904.
3.
Mizuno T, Shu IW, Makimura H, et al. Obesity over the life course. Sci Aging Knowledge Environ. 2004;2004(24):re4.CrossRefPubMed
4.
Fontaine KR, Redden DT, Wang C, et al. Years of life lost due to obesity. JAMA. 2003;289(2):187–93.CrossRefPubMed
5.
Sowemimo OA, Yood SM, Courtney J, et al. Natural history of morbid obesity without surgical intervention. Surg Obes Relat Dis. 2007;3(1):73–7. discussion 77CrossRefPubMed
6.
Goodrick GK, Poston 2nd WS, Foreyt JP. Methods for voluntary weight loss and control: update. Nutrition. 1996;12:672–6.CrossRefPubMed
7.
Knowler WC, Barrett-Connor E, Fowler SE, et al. and Group, Diabetes Prevention Program Research. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2007;346(6):393–403.
8.
Caterson ID, Finer N, Coutinho W, et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab. 2012;14(6):523–30.CrossRefPubMed
9.
Goldstein JD. Beneficial health-effects of modest weight-loss. Int J Obes. 1992;16:397–415.
10.
11.
Inc., Apollo Endosurgery. Orbera TM intragastric balloon system (Orbera TM). San Diego: Apollo Endosurgery, 2015;1–30.
12.
13.
14.
Nieben OG, Harboe H. Intragatric balloon as an artificial bezoarfor treatment of obesity. Lancet. 1982;1:198–9.CrossRefPubMed
15.
McFarland RJ, Grundy A, Gazet JC, et al. The intragastric balloon: a novel idea proved ineffective. Br J Surg. 1987;74(2):137–9.CrossRefPubMed
16.
Kirby DF, Mills PR, Kellum JM, et al. Incomplete small bowel obstruction by the Garren-Edwards gastric bubble necessitating surgical intervention. Am J Gastroenterol. 1987;82:251–3.PubMed
17.
Kramer FM, Stunkard AJ, Spiegel TA, et al. Limited weight losses with a gastric balloon. Arch Intern Med. 1989;149(2):411–3.CrossRefPubMed
18.
19.
Brooks J, Srivastava ED, Mathus-Vliegen EM. One-year adjustable intragastric balloons: results in 73 consecutive patients in the U.K. Obes Surg. 2014;24(5):813–9.CrossRefPubMed
20.
Machytka E, Klvana P, Kornbluth A, et al. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obes Surg. 2011;21(10):1499–507.CrossRefPubMedPubMedCentral
21.
Giardiello C, Borrelli A, Silvestri E, et al. Air-filled vs water-filled intragastric balloon: a prospective randomized study. Obes Surg. 2012;22(12):1916–9.CrossRefPubMed
22.
Fuller NR, Pearson S, Lau NS, et al. An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study. Obesity (Silver Spring). 2011;21(8):1561–70.CrossRef
23.
Almeghaiseeb ES, Ashraf MF, Alamro RA, et al. Efficacy of intragastric balloon on weight reduction: Saudi perspective. World J Clin Cases. 2017;5(4):140–7.CrossRefPubMedPubMedCentral
24.
Laing P, Pham T, Taylor LJ, et al. Filling the void: a review of intragastric balloons for obesity. Dig Dis Sci. 2017;62(6):1399–408.CrossRefPubMed
25.
Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis. 2015;11:874–81.CrossRefPubMed
26.
Imaz I, Martínez-Cervell C, García-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18(7):841–6.CrossRefPubMed
27.
Ali MR, Moustarah F, Kim JJ. American Society for Metabolic and Bariatric Surgery Clinical Issues Committee. American Society for Metabolic and Bariatric Surgery position statement on intragastric balloon therapy endorsed by the Society of American Gastrointestinal and Endoscopic Surgeons. Surg Obes Relat Dis. 2016;12(3):462–7.CrossRefPubMed
28.
Yorke E, Switzer NJ, Reso A, et al. Intragastric balloon for management of severe obesity: a systematic review. Obes Surg. 2016;26(9):2248–54.CrossRefPubMed
29.
Kumar N, Bazerbachi F, Rustagi T, McCarty TR, Thompson CC, Galvao Neto MP,Zundel N, Wilson EB, Gostout CJ, Abu Dayyeh BK. The influence of the orbera intragastric balloon filling volumes on weight loss, tolerability, and adverse events: a systematic review and meta-analysis. Obes Surg, 2017;12.
30.
Escudero Sanchis A, Catalán Serra I, Gonzalvo Sorribes J, et al. Effectiveness, safety, and tolerability of intragastric balloon in association with low-calorie diet for the treatment of obese patients. Rev. Esp Enferm Dig. 2008;100(6):349–54. SpanishCrossRefPubMed
31.
Alfredo G, Roberta M, Massimiliano C, et al. Long-term multiple intragastric balloon treatment—a new strategy to treat morbid obese patients refusing surgery: prospective 6-year follow-up study. Surg Obes Relat Dis. 2014;10:307–11.CrossRefPubMed
32.
Melissas J. IFSO Guidelines for safety, quality, and excellence in bariatric surgery. Obes Surg. 2008;18:497–500.CrossRefPubMed
33.
Sarela AI, Dexter SP, O’Kane M, et al. Long-term follow-up after laparoscopic sleeve gastrectomy: 8–9-year results. Surg Obes Relat Dis. 2012;8(6):679–84.CrossRefPubMed
34.
Keren D, Matter I, Lavy A. Lifestyle modification parallels to sleeve success. Obes Surg. 2014;24(5):735–40.CrossRefPubMed
35.
Keren D, Matter I, Rainis T, et al. Getting the most from the sleeve: the importance of post-operative follow-up. Obes Surg. 2011;21(12):1887–93.CrossRefPubMed
36.
Dastis NS, Francois E, Deviere J, et al. Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years. Endoscopy. 2009;41:575–80.CrossRefPubMed
37.
Genco A, Balducci S, Bacci V, et al. Intragastric balloon or diet alone? A retrospective evaluation. Obes Surg. 2008;18(8):989–92.CrossRefPubMed
Metadata
Title
Intragastric Balloons for Overweight Populations—1 Year Post Removal
Authors
Dean Keren
Tova Rainis
Publication date
01-08-2018
Publisher
Springer US
Published in
Obesity Surgery / Issue 8/2018
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-018-3167-2

Other articles of this Issue 8/2018

Obesity Surgery 8/2018 Go to the issue

Original Contributions

Can Helicobacter pylori Eradication Treatment Modify the Metabolic Response to Bariatric Surgery?

Original Contributions

Contribution of Type 2 Diabetes Mellitus to Subclinical Atherosclerosis in Subjects with Morbid Obesity

Letter to the Editor

Comments on “Challenges in Transition of Care for Pediatric Patients after Weight-Reduction Surgery: a Systematic Review and Recommendations for Comprehensive Care”

Original Contributions

Bariatric Surgery in the Elderly Is Associated with Similar Surgical Risks and Significant Long-Term Health Benefits

Brief Communication

Changes in Cerebral Cortical Thickness Related to Weight Loss Following Bariatric Surgery

Original Contributions

Alcohol Consumption in Obese Patients Before and After Gastric Bypass as Assessed with the Alcohol Marker Phosphatidylethanol (PEth)